223. SERDs, SERMs, CERANs, and PROTACs episode artwork

EPISODE · Feb 11, 2024 · 11 MIN

223. SERDs, SERMs, CERANs, and PROTACs

from Breast Cancer Conversations · host SurvivingBreastCancer.org

Love the podcast? Send us a text!Today, we had the pleasure of having Melanie Sisk on the show to demystify the complex world of emerging endocrine therapies, often referred to as the "alphabet soup" of treatments. Melanie provided clarity on the different classes of drugs and how they interact with tumors, particularly focusing on those that target estrogen receptors.We discussed:SERMs (Selective Estrogen Receptor Modulators): These drugs, like tamoxifen, block the growth of cancer cells by competing with estrogen receptors.SERDs (Selective Estrogen Receptor Down Regulators/Degraders): Drugs like Fluvestrant work by degrading estrogen receptors.SERANs (Complete Estrogen Receptor Antagonists): These block both pathways of estrogen, offering a complete blockade.PROTACs: A newer class that targets specific proteins, such as the estrogen receptor, to inhibit cancer growth.+++++++++++++++++++++Attend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramLaura and Will: https://www.instagram.com/laura_and_will/SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the showListener FeedbackIf this episode resonated with you, we invite you to leave a review on Apple Podcasts or Spotify.You can also click the link in the show notes that says "Love this episode? Send us a text" to share feedback.Messages are completely anonymous.If you would like us to follow up directly, please include your email address in your message so we can respond.Latest News: Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources from SurvivingBReastCancer.org! Become a Breast Cancer Conversations+ Member! Sign Up Now. Enjoying our content? Please consider supporting our work. 

Episode metadata supplied by the publisher feed · Published Feb 11, 2024

Embed this episode

Love the podcast? Send us a text! Today, we had the pleasure of having Melanie Sisk on the show to demystify the complex world of emerging endocrine therapies, often referred to as the "alphabet soup" of treatments. Melanie provided clarity on the different classes of drugs and how they interact with tumors, particularly focusing on those that target estrogen receptors. We discussed: SERMs (Selective Estrogen Receptor Modulators): These drugs, like tamoxifen, block the growth of cancer cells ...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

223. SERDs, SERMs, CERANs, and PROTACs

0:00 11:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Breast Cancer Conversations?

This episode is 11 minutes long.

When was this Breast Cancer Conversations episode published?

This episode was published on February 11, 2024.

Can I download this Breast Cancer Conversations episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!